Pfiz­er, Mer­ck KGaA hit the brakes on an­oth­er PhI­II as PD-L1 Baven­cio flops yet again

Pfiz­er and Mer­ck KGaA are ce­ment­ing in their dis­tant run­ner-up sta­tus for Baven­cio (avelum­ab), a PD-L1 check­point that just failed its fourth late-stage tri­al. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.